<DOC>
	<DOCNO>NCT00567671</DOCNO>
	<brief_summary>Prospective , randomize , single site study determine safety effectiveness perform corneal collagen cross-linking ( CCCL ) use riboflavin UVA light eye corneal ectasia progressive keratoconus .</brief_summary>
	<brief_title>Corneal Collagen Cross-Linking Treatment Progressive Keratoconus Corneal Ectasia</brief_title>
	<detailed_description>Subjects randomize control group treatment group , control group cross treatment group 3 month visit . Corneal collagen cross-linking perform single treatment . Subjects follow least 12 month evaluate long term effect corneal collagen cross-linking . Subjects may refer physician must return Emory Vision completion study visit .</detailed_description>
	<mesh_term>Keratoconus</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Corneal Diseases</mesh_term>
	<criteria>Diagnosis keratoconus document progression previous 12 month . Diagnosis corneal ectasia Must able complete study visit Prior corneal surgery keratoconus group Corneal scarring</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>keratoconus</keyword>
	<keyword>ectasia</keyword>
	<keyword>cross-linking</keyword>
	<keyword>riboflavin</keyword>
	<keyword>UVA light</keyword>
	<keyword>cornea</keyword>
</DOC>